LPAR1 (lysophosphatidic acid receptor 1) is a G protein-coupled receptor that serves as the primary cellular receptor for lysophosphatidic acid (LPA) 1. The receptor activates multiple downstream signaling cascades including G(i)/G(o), G(12)/G(13), and G(q) families, leading to decreased cAMP levels, increased cytoplasmic calcium, and activation of phospholipase C and MAP kinases 2. LPAR1 mediates Rho-dependent actin cytoskeleton reorganization and promotes cell migration, differentiation, and proliferation, contributing to responses to tissue injury and infection 2. Clinically, LPAR1 has emerged as a therapeutic target in multiple fibrotic diseases. Elevated LPA levels and LPAR1 activation contribute to pathophysiology in idiopathic pulmonary fibrosis and systemic sclerosis, where LPAR1 inhibition reduces collagen deposition and inflammation 3. In liver fibrosis, LPAR1 blockade inhibits pathological collagen production by central vein-associated hepatic stellate cells 4. The LPA-LPAR1 axis also mediates HIV-related liver fibrosis through PI3K/AKT-dependent YAP activation 5. Beyond fibrosis, LPAR1 is essential for normal skeleton and brain development, plays roles in neuropathic pain, hypertension susceptibility, and skin barrier function via keratinocyte differentiation 678. LPAR1 inhibitors represent promising therapeutic agents for multiple organ system pathologies with significant unmet clinical needs.